ReviewExperimental hematology & oncology2026

Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes.

Jiacheng Lou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.